Health Condition 1: B159- Hepatitis A without hepatic coma
Conditions
Interventions
Intervention1: Arq-e-Mako, Arq-e-Kasni: Dose will be administered orally, twice a day before meal for 21 days.
The dose will be calculated as a proportion of the adult dose of 120 ml.
Age group 2 to
Sponsors
State Unani Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Patients of either gender. Patients aged 2 to 18 years. Clinically diagnosed or presumptive cases of hepatitis A. IgM anti-HAV positive cases. Elevated ALT or AST above the upper limit of normal. Guardians or parents willing to provide informed consent and follow the study protocol.
Exclusion criteria
Exclusion criteria: Patients of hepatitis A with complications such as hepatic cellular failure where PT-INR is more than 2 without hepatic encephalopathy, or more than 1.5 with hepatic encephalopathy. Hepatitis A associated with systemic or chronic diseases such as tuberculosis, cardiac disease, renal disease, or other hepatic diseases. Known cases of hepatitis B, hepatitis C, hepatitis E, or drug-induced hepatitis. Patients receiving any other therapy within the last 3 days. Patients who are unsure about attending study visits regularly.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in biochemical parameters, namely ALT, AST, ALP, and total serum bilirubin. Timepoint: Biochemical parameters will be assessed at baseline, 14th day, and 21st day. | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving clinical recovery as evidenced by clinical parameters such as fever, weakness, nausea and vomiting, icterus, and tender or enlarged liver. Timepoint: Clinical parameters will be assessed at baseline, 7th day, 14th day, and 21st day. | — |
Countries
India
Contacts
Public ContactZuber Ahmad
State Unani Medical College and Hospital
Outcome results
None listed